MaxCyte, Inc. MaxCyte Announces Research Agreement with Kite (9788G)
12 November 2018 - 6:00PM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 9788G
MaxCyte, Inc.
12 November 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
MaxCyte Announces Research Agreement
with Kite, a Gilead Company
Gaithersburg, Maryland - 12 November 2018: MaxCyte (LSE: MXCT,
MXCR), the global cell-based medicines and life sciences company,
announced today that it has entered into a research agreement with
Kite, a Gilead Company. Under the terms of the agreement, Kite will
use MaxCyte's Flow Electroporation(R) Technology platform to enable
non-viral cell engineering.
"We're excited to provide Kite the ability to leverage our
versatile cell engineering platform to enable gene-editing
technologies for research and development of important new
therapeutics," said Doug Doerfler, President & CEO of MaxCyte,
Inc. "This agreement further underlines MaxCyte's position as a
leader in non-viral cell engineering for cell therapies."
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences
company applying its patented cell engineering technology platform
to help patients with high unmet medical needs in a broad range of
conditions. MaxCyte is developing novel CARMA therapies for its own
pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for
autologous cell therapy. In addition, through its core business,
MaxCyte leverages its Flow Electroporation(R) Technology platform
to enable its biopharmaceutical industry partners to advance the
development of innovative, cutting-edge medicines, particularly in
cell therapy, including the use of gene editing tools in the
treatment of inherited genetic diseases and immuno-oncology
approaches to treating cancer. MaxCyte has placed its cutting-edge
flow electroporation instruments worldwide, with all of the top ten
global biopharmaceutical companies, has more than 55 partnered
programme licences in cell therapy including more than 25 licensed
for clinical use. With its robust delivery technology platform,
MaxCyte helps its partners to unlock the full potential of their
products. For more information, visit www.maxcyte.com.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGREADFFFEDPFAF
(END) Dow Jones Newswires
November 12, 2018 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024